Press release
Persistent Pulmonary Hypertension of the Newborn (PPHN) Market 2025-2034 Business Outlook, Critical Insight and Growth
Persistent Pulmonary Hypertension of the Newborn (PPHN) Market
Persistent Pulmonary Hypertension of the Newborn (PPHN) is a life-threatening condition where a newborn's circulation system fails to adapt to breathing outside the womb. It leads to high pulmonary artery pressure, low oxygen levels, and severe respiratory distress. Affecting approximately 1 in every 500-700 live births, PPHN remains a critical challenge in neonatal intensive care units (NICUs).
The PPHN Market is expanding as healthcare systems improve neonatal care infrastructure, therapies such as inhaled nitric oxide (iNO) and PDE-5 inhibitors become widely adopted, and research into novel treatments advances. From 2024 to 2034, the market will grow steadily, supported by increasing NICU admissions, better survival rates, and strong R&D pipelines.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/71496
Market Overview
• Market Size 2024: Estimated at USD 1.3 billion
• Forecast 2034: Projected to reach USD 2.9 billion
• CAGR (2024-2034): ~8.2%
Key Highlights
• Rising prevalence of PPHN in both developed and developing regions.
• Inhaled nitric oxide remains the gold-standard therapy.
• Increasing use of PDE-5 inhibitors (sildenafil) and prostacyclin analogs in refractory cases.
• Growing role of extracorporeal membrane oxygenation (ECMO) in severe cases.
Segmentation Analysis
By Drug Class
• Inhaled Nitric Oxide (iNO)
• Phosphodiesterase-5 (PDE-5) Inhibitors (sildenafil, tadalafil)
• Prostacyclin Analogs (epoprostenol, iloprost)
• Endothelin Receptor Antagonists (bosentan, ambrisentan)
• Others (calcium channel blockers, supportive therapies)
By Therapy Type
• Monotherapy
• Combination Therapy
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By End User
• Hospitals & NICUs
• Pediatric Specialty Clinics
• Ambulatory Care Centers
Summary:
The market is dominated by hospital-based therapies like iNO, but combination regimens with PDE-5 inhibitors and prostacyclins are increasingly adopted for refractory cases. Research into endothelin receptor antagonists and gene therapies is expected to expand future treatment options.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/71496/persistent-pulmonary-hypertension-of-the-newborn-market
Regional Analysis
North America
• Largest market in 2024 due to high NICU availability and strong adoption of iNO.
• The U.S. leads with advanced neonatal care standards and FDA-approved therapies.
• Significant use of ECMO in severe PPHN cases.
Europe
• Germany, France, and the UK driving market growth.
• Government support for rare neonatal disease research and orphan drug approvals.
• Strong adoption of prostacyclin analogs and PDE-5 inhibitors in combination with iNO.
Asia-Pacific
• Fastest-growing region (CAGR ~9.4%).
• Large newborn population in India and China.
• Rising NICU infrastructure and government-backed neonatal health initiatives.
• Japan and South Korea leading in neonatal R&D and early adoption of advanced therapies.
Latin America
• Brazil and Mexico showing steady growth.
• Limited access to advanced therapies outside urban centers.
• Increasing awareness and government investments in neonatal care.
Middle East & Africa
• Smaller share but improving NICU capacity in GCC countries.
• High neonatal mortality rates in Sub-Saharan Africa due to limited access.
• International aid programs helping improve care availability.
Summary:
While North America and Europe dominate today, Asia-Pacific will be the fastest-growing market, driven by its large neonatal population, rising NICU investments, and improved healthcare access.
Market Dynamics
Key Growth Drivers
• Rising prevalence of PPHN globally.
• Expansion of NICU capacity in emerging economies.
• Strong adoption of iNO and PDE-5 inhibitors as standard treatments.
• Advancements in ECMO technologies for critical cases.
Key Challenges
• High treatment costs, especially for ECMO and long-term NICU care.
• Limited availability of advanced therapies in low-income regions.
• Risk of complications and side effects associated with therapies.
Latest Trends
• Development of next-gen nitric oxide delivery systems.
• Clinical trials exploring endothelin receptor antagonists for neonatal use.
• Integration of AI-based neonatal monitoring platforms for early detection of hypoxemia.
• Growing research into gene therapy and regenerative medicine for pulmonary hypertension.
Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71496
Competitor Analysis
Major Players
• Mallinckrodt Pharmaceuticals - INOmax (inhaled nitric oxide).
• United Therapeutics Corporation - Prostacyclin analogs.
• Pfizer Inc. - Sildenafil (widely used in neonatal pulmonary hypertension).
• Novartis AG - Expanding cardiovascular and rare disease portfolio.
• GlaxoSmithKline plc (GSK) - Pediatric respiratory therapies.
• Bayer AG - PDE-5 inhibitors and pulmonary hypertension drugs.
• Actelion Pharmaceuticals (Johnson & Johnson) - Endothelin receptor antagonists.
• Chiesi Farmaceutici - Neonatal and rare respiratory disease focus.
• AbbVie Inc. - Pediatric care portfolio.
• Emerging Biotechs - Advancing neonatal-specific R&D in pulmonary hypertension.
Competitive Summary:
The market is led by Mallinckrodt's INOmax, the standard of care for PPHN, while Pfizer, Bayer, and United Therapeutics provide key adjunct therapies. Actelion (J&J) and biotech innovators are driving next-generation drug development, focusing on refractory and severe cases.
Conclusion
The Persistent Pulmonary Hypertension of the Newborn (PPHN) Market is projected to grow from USD 1.3 billion in 2024 to USD 2.9 billion by 2034, at a CAGR of 8.2%. Rising neonatal ICU admissions, improved survival rates, and strong R&D activity in vasodilators and biologics will drive this growth.
While affordability and access remain challenges, especially in low-income countries, opportunities lie in AI-driven neonatal monitoring, next-generation nitric oxide systems, and novel drug classes.
Key Takeaway: Companies that invest in innovative neonatal pulmonary therapies, advanced monitoring systems, and affordable access models will be best positioned to lead the PPHN market through 2034.
This report is also available in the following languages : Japanese (新生児持続性肺高血圧症), Korean (신생아 시장의 지속성 폐 고혈압), Chinese (新生儿持续性肺动脉高压市场), French (Hypertension pulmonaire persistante du marché des nouveau-nés), German (Persistierende pulmonale Hypertonie des Neugeborenenmarktes), and Italian (Ipertensione polmonare persistente del neonato), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71496
Our More Reports:
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Market
https://exactitudeconsultancy.com/reports/71690/familial-hypercholesterolemia-type-ii-hyperlipoproteinemia-market
Idiopathic CD4+ Lymphocytopenia Market
https://exactitudeconsultancy.com/reports/71692/idiopathic-cd4-lymphocytopenia-market
Laband Syndrome Market
https://exactitudeconsultancy.com/reports/71694/laband-syndrome-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
IRFAN TAMBOLI
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Persistent Pulmonary Hypertension of the Newborn (PPHN) Market 2025-2034 Business Outlook, Critical Insight and Growth here
News-ID: 4168358 • Views: …
More Releases from Exactitude Consultancy
Hypertrophic Cardiomyopathy Market to Reach USD 3.21 Billion by 2034, Growing at …
Introduction
Hypertrophic cardiomyopathy (HCM) is a genetic heart disorder characterized by abnormal thickening of the heart muscle, which can impair blood flow and increase the risk of arrhythmias, heart failure, and sudden cardiac death. Once managed primarily through beta-blockers, calcium channel blockers, and invasive procedures, the HCM treatment landscape has expanded with the approval of targeted therapies such as cardiac myosin inhibitors.
Growing awareness of genetic cardiovascular diseases, advances in molecular diagnostics,…
Biologics Contract Research Organization (CRO) Market to Reach USD 37.9 Billion …
Introduction
Biologics-including monoclonal antibodies, vaccines, recombinant proteins, and advanced therapies-are at the forefront of modern medicine. Their development, however, requires significant expertise, advanced infrastructure, and compliance with stringent regulatory standards. To meet these demands, pharmaceutical and biotechnology companies are increasingly outsourcing to Contract Research Organizations (CROs) specializing in biologics.
Biologics CROs provide services spanning discovery, preclinical research, clinical trials, bioanalytical testing, and regulatory consulting. With the rise of biologics, biosimilars, and advanced…
Niemann-Pick Disease Market to Reach USD 1.02 Billion by 2034, Growing at 10.6% …
Introduction
Niemann-Pick disease (NPD) is a group of rare, inherited lysosomal storage disorders caused by mutations that disrupt lipid metabolism, leading to progressive neurological decline, organ dysfunction, and premature death. The condition is categorized into several subtypes (A, B, and C), each varying in severity and progression.
Historically, treatment has been limited to palliative and supportive care. However, the landscape is changing rapidly with the development of enzyme replacement therapies (ERT), substrate…
PERK Inhibitors Market Forecast: USD 3.2 Billion by 2034 | Major Participants: N …
The fight against cancer and neurodegenerative diseases has brought the spotlight on the PERK (Protein kinase RNA-like endoplasmic reticulum kinase) pathway, a critical regulator of the unfolded protein response. PERK inhibitors are designed to modulate this pathway, reducing stress-induced cell death and playing a pivotal role in oncology, neurodegenerative research, and metabolic disorders. As precision medicine continues to gain traction, PERK inhibitors are attracting significant attention from both biotech firms…
More Releases for PPHN
Global Inhaled Nitric Oxide Market Insights - Industry Share, Sales Projections, …
Nitric oxide is a chemical compound in gas form that is sometimes used to treat infants with severe breathing problems associated with narrow blood vessels in the lungs. It works by relaxing smooth muscle to widen (dilate) blood vessels, especially in the lungs. Nitric oxide is usually used together with a breathing machine (ventilator).
Inhaled nitric oxide (iNO) is recognized as a potent and selective pulmonary vasodilator that does not decrease…
Inhaled Nitric Oxide Market Study Upto 2027| Mallinckrodt, Praxair (Linde plc), …
Nitric oxide is a chemical compound in gas form that is sometimes used to treat infants with severe breathing problems associated with narrow blood vessels in the lungs. It works by relaxing smooth muscle to widen (dilate) blood vessels, especially in the lungs. Nitric oxide is usually used together with a breathing machine (ventilator). Inhaled nitric oxide (iNO) is recognized as a potent and selective pulmonary vasodilator that does not…
$ 920.0 Million Opportunity by 2024 in the World Inhaled Nitric Oxide Market and …
The Global "Inhaled Nitric Oxide Market” The quick adoption of advanced analytics and visualization, and the expand use of outward data sources are the major drivers of the Inhaled Nitric Oxide Market. The report high point, potential growth opportunities in the coming years and covers a review of the market drivers, growth measure, competitive landscape, market dynamics, opposition and other feature to the Inhaled Nitric Oxide Market.
Global Inhaled Nitric Oxide…
Inhaled Nitric Oxide Market to hit 1490 million US$ by 2025: QY Research, Inc.
A market research report is a perfect tool for digging deep into critical aspects of the global Inhaled Nitric Oxide market and closely understanding factors that influence its growth. Our research analysts are experienced enough to provide you with the right information about the global Inhaled Nitric Oxide market to help your business propel forward in the coming years. What makes us different from other market researchers is our high…
Inhaled Nitric Oxide Market Will Reach 1490 Million US$ by 2025
This report studies the global Inhaled Nitric Oxide market status and forecast, categorizes the global Inhaled Nitric Oxide market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa.Nitric oxide is a chemical compound in gas form that is sometimes used to treat infants with severe breathing problems associated with…
Global Nitric Oxide Industry Research Report, Growth Trends and Competitive Anal …
This study focuses on the production side and consumption side of Nitric Oxide, presents the global Nitric Oxide market size by manufacturers, regions, type and application, history breakdown data from 2013 to 2018, and forecast to 2025.
In terms of production side, this report researches the Nitric Oxide capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and product type.
In terms of consumption side, this…
